Holen Sie sich die Stockscreener-App
2.187
1.25%
0.027
Schlusskurs vom Vortag:
$2.16
Offen:
$2.12
24-Stunden-Volumen:
11,437
Relative Volume:
0.54
Marktkapitalisierung:
$3.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.77M
KGV:
-0.8264
EPS:
-2.6464
Netto-Cashflow:
$-2.69M
1W Leistung:
+1.25%
1M Leistung:
+0.55%
6M Leistung:
-0.41%
1J Leistung:
-46.87%
1-Tages-Spanne:
$2.12
$2.245
1-Wochen-Bereich:
$2.03
$2.245
52-Wochen-Spanne:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Firmenname
Xortx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare XRTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.187 | 3.50M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
529.65 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.00 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
864.74 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.55 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail
Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan
XORTX says board chair Anthony Giovinazzo resigns for personal reasons - Bitget
XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com
XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks
XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan
XORTX Board Gains Director With Over 20 Years in Financial Services - Stock Titan
Vectus Biosystems Appoints Dr Tara Speranza as CEO and CTO, Raises $791,000 to Accelerate VB0004 Clinical Development - Kalkine
Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.025|Chg%:-0.090 - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.015|Chg%:-0.010 - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XORTX Therapeutics Inc. Revenue Breakdown – NASDAQ:XRTX - TradingView
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XORTX Therapeutics, Inc. Revenue Breakdown – NEO:XRTX - TradingView
XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News - Moomoo
XORTX Therapeutics (XRTX) Investor presentation Summary - Quartr
XORTX Therapeutics (XRTX) Q4 2024 earnings summary - Quartr
Price to earnings forward of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView
XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains MomentumMoney Flow - dars.gov.et
XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum BuildsDescending Triangle - dars.gov.et
XRTX Q1 2024 Earnings: Pre‑Revenue Biotech Reports EPS Miss as Clinical Pipeline AdvancesDiluted EPS Report - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Xortx Therapeutics updates investors on kidney disease focus - ad-hoc-news.de
XORTX Therapeutics Company Profile & Introduction - Moomoo
XRTX Q1 2024 Earnings: Significant EPS Miss Reflects Preclinical Stage ChallengesQuarterly Earnings - dars.gov.et
Enterprise value to EBIT forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Price to sales forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Enterprise value to revenue forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Why XORTX Therapeutics Inc stock is skyrocketing today - Wealth Awesome
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
XRTX Q1 2024 Earnings: Significant EPS Miss Highlights Challenges in Clinical-Stage BiotechEarnings Growth Analysis - dars.gov.et
XRTX Q1 2024 Earnings: Significant EPS Miss Amid Operational DevelopmentsEarnings Surprise Stocks - DonanımHaber
XORTX Therapeutics (XRTX) Edges Higher as Stock Remains Within Defined RangeLong Short Pair - DonanımHaber
XORTX Therapeutics Inc. (XRTX) Slides 2.79% as Shares Test Key Support Near $2.00IV Percentile - dars.gov.et
XORTX Therapeutics Inc (XRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
XORTX Therapeutics Q1 2024 Earnings: Significant EPS Miss Reflects R&D Investment, Stock Gains Despite Loss - newsline.com
XORTX Therapeutics (XRTX) Gains 1.43% as Shares Approach Resistance at $2.24Virgin POC - dars.gov.et
XORTX Therapeutics (XRTX) Slips 0.68% as Traders Eye Key Support at $2.06Covered Call ETF - newsline.com
XORTX Therapeutics appoints Mika Grasso as co‑CEO - MSN
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange - marketscreener.com
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO - marketscreener.com
Finanzdaten der Xortx Therapeutics Inc-Aktie (XRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):